^
    Back
    Association details:
    Biomarker:CCDC170 overexpression
    Cancer:Breast Cancer
    Drug:paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Aging (Albany NY)
    Title:

    CCDC170 affects breast cancer apoptosis through IRE1 pathway

    Published date:
    12/03/2020
    Excerpt:
    MCF7 cells overexpressing CCDC170 were more sensitive to paclitaxel. Our study showed that higher CCDC170 expression is associated with a better prognosis in breast cancer patients and that CCDC170 may promote apoptosis through the IRE1α pathway.
    DOI:
    10.18632/aging.202315